Cargando…
FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine
Autores principales: | Luh, Frank, Yen, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170456/ https://www.ncbi.nlm.nih.gov/pubmed/30302274 http://dx.doi.org/10.1038/s41525-018-0067-2 |
Ejemplares similares
-
Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations
por: Issa, Amalia M., et al.
Publicado: (2018) -
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019) -
Advancing digital health: FDA innovation during COVID-19
por: Kadakia, Kushal, et al.
Publicado: (2020) -
Paxlovid(TM) Information From FDA and Guidance for AES
Members
por: Cokley, Jon A., et al.
Publicado: (2022) -
Right data for right patient—a precisionFDA NCI–CPTAC Multi-omics Mislabeling Challenge
por: Boja, Emily, et al.
Publicado: (2018)